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(EGPA). Since 2009, there have been many ad‑
vances in the therapeutics and long ‑term moni‑
toring of these conditions, leading to a sea change 
in the way that they are treated. In the interest of 
cross ‑specialty working, the EULAR and the Eu‑
ropean Renal Association joined hands and com‑
missioned a task force of experts from 13 coun‑
tries to update the 2009 recommendations with 
a focus on AAV. Those recommendations have 
just been published.2
Why do we need recommendations? AAV are rare, 
with an annual incidence of 10 to 20 per million 
in Northern Europe.3 This means that the average 
clinician might not see more than a handful of pa‑
tients in their career. It is important to empower 
Introduction The European League Against Rheu‑
matism (EULAR) published recommendations 
for the management of primary small and medi‑
um vessel vasculitis in 2009.1 Among these are 
a group of vasculitides united in their associa‑
tion with antibodies directed against antigenic 
targets (myeloperoxidase [MPO] or proteinase 3 
[PR3]) in the neutrophil cytoplasm—the antineu‑
trophil cytoplasmic antibodies (ANCA). ANCA‑
‑associated vasculitides (AAV) predominantly af‑
fect the vessels of small or medium caliber, pro‑
ducing necrotizing inflammation with a few or 
no immune deposits. The 3 distinct phenotypes 
in this group are granulomatosis with polyangi‑
itis (GPA), microscopic polyangiitis (MPA), and 
eosinophilic granulomatosis with polyangiitis 
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ABSTRACT
The European League against Rheumatism (EULAR) with the European Renal Association – European 
Dialysis and Transplant Association recently published an update of 2009 EULAR recommendations with 
a focus on the management of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV). 
In this article, we discuss the following key messages for clinical practice derived from these recom-
mendations: 1) biopsy should be performed if possible to confirm new diagnosis or relapse; 2) glucocor-
ticoid therapy is an extremely important adjunct to the management of AAV, but it is also responsible 
for the majority of adverse effects; the dose should be tapered to 7.5 to 10 mg/d at 3 to 5 months; 3) 
cyclophosphamide or rituximab are the mainstay of remission induction; 4) patients with major relapse 
should be treated like those with new disease, but rituximab is the preferred option in those patients who 
relapse after prior cyclophosphamide; 5) minor relapse should not be treated with glucocorticoid alone, 
and a change in immunosuppressive regimen should be considered; 6) rituximab can be used not only 
for remission induction but also for maintenance; 7) maintenance therapy should continue for at least 2 
years, after which gradual taper could be considered; 8) while ANCA are extremely useful for diagnosis 
and rising ANCA levels seem to be associated with relapse, serial monitoring should not guide treat-
ment decisions; 9) monitoring of AAV patients should be holistic with a structured assessment tool and 
monitoring for effects related to the vasculitis as well as treatment; 10) management should be either 
at or in conjunction with an expert center; and 11) patients should be involved in decision making and 
have access to educational resources.
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GPA and MPA because of the paucity of evidence 
for the treatment of EGPA.
Diagnosis AAV do not have any diagnostic crite‑
ria or any pathognomonic tests. Diagnostic cri‑
teria are in development but currently diagno‑
sis relies on pattern recognition.8 When classifi‑
cation criteria are used for diagnostic purposes, 
the results are disappointing.9 The new recom‑
mendations do not make specific recommenda‑
tions about diagnostic workup but do comment 
on the role of biopsy. A positive biopsy is strong‑
ly supportive of a diagnosis of vasculitis; there‑
fore, this confirmation should be sought when‑
ever possible. A positive ANCA test (anti ‑PR3 
or anti ‑MPO) in the correct clinical context has 
a very high specificity for the diagnosis of small 
vessel vasculitis.10 However, localized disease may 
be ANCA negative.11 Therefore, a positive biopsy 
has a greater role to play in ANCA ‑negative dis‑
ease. The diagnostic yield depends on the biopsied 
organ. Generally, renal biopsies have a greater di‑
agnostic yield compared to ENT biopsies.2 Trans‑
bronchial biopsies have a much lower yield than 
open lung biopsies and are generally reserved for 
situations of diagnostic uncertainty where tissue 
may not be available from other sources. Biopsies 
also offer prognostic information.12,13 For exam‑
ple, a greater proportion of sclerotic glomeruli in 
a biopsy is associated with an adverse prognosis.
the average clinician to be able to make decisions 
in a standardized way and know when to ask for 
help from a specialist center. Recommendations 
provide an authoritative way for patients and cli‑
nicians to access specialist services and high ‑cost 
drugs. AAV have a high mortality rate if they re‑
main untreated.4 With improved therapeutics, pa‑
tients are surviving longer,5 but their monitoring 
and educational needs are changing.6,7 The recom‑
mendations form the basis for regulatory author‑
ities to plan availability of high ‑cost drugs and ac‑
cess to specialist services. Recommendations al‑
low standardization of teaching undergraduate 
and postgraduate trainees. They provide the pri‑
mary and secondary care physicians with surro‑
gate experience from experts in the field.
AAV crosses organ boundaries and can pres‑
ent to various specialists. To allow for true mul‑
tisystem collaboration in the formation of these 
recommendations, the EULAR / European Renal 
Association – European Dialysis and Transplant 
Association (ERA ‑EDTA) task force consisted of 
representation from rheumatology, renal medi‑
cine, internal medicine, ororhinolaryngology (ear, 
nose & throat – ENT), ophthalmology, patholo‑
gy, chest medicine, clinical immunology, nurs‑
ing, and a patient support group. In this article, 
we discuss the key messages for clinical practice 
derived from these multispecialty recommenda‑
tions. However, we will restrict our discussion to 
FIGURE 1 EULAR/
ERA -EDTA algorithm for 
the management of new  
antineutrophil cytoplasmic 
antibody  (ANCA)-
-associated vasculitis. 
Dashed lines indicate 
suggested alternative or 
supplementary action to 
consider. Reproduced 
from “EULAR/ERA -EDTA 
recommendations for 
the management of 
ANCA -associated 
vasculitis. Yates M, Watts 
RA, Bajema IM, et al. 
2016; 75 (9): 1583- 
-1594” with permission 
from BMJ Publishing 
Group Ltd.
non-organ-threatening disease
methotrexate or mycophenolate 
mofetil with glucocorticoid
new diagnosis of ANCA-associated vasculitis
organ or life-threatening disease
cyclophosphamide or rituximab 
with glucocorticoid
remission
azathioprine or methotrexate 
or rituximab  
continue glucocorticoid taper
after 2 years, taper azathioprine 
or methotrexate 
stop rituximab
rapidly progressive renal failure
or
pulmonary hemorrhage
consider plasma exchange
refractory
• seek expert opinion
• re-evaluate diagnosis
• optimize treatment
• consider other drugs
relapse
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regimen would prove effective in centers without 
infusion facilities. With either regimen, induction 
therapy is given until remission is achieved, but 
for not less than 3 months and not more than 6 
months. The dose should be adjusted for age and 
renal function (TABLE 1). It is recommended that 
standard protocols used in oncology are adapt‑
ed for use of cyclophosphamide in rheumatic dis‑
eases. All patients should be well hydrated during 
therapy, and prehydration with antiemetic medi‑
cations is recommended with an intravenous pro‑
tocol. Mesna (2 ‑mercaptoethane sulfonate sodi‑
um) can be given either orally or intravenously to 
prevent bladder toxicity. Patients should be mon‑
itored for leukopenia and the dose should be re‑
duced according to local protocols. Oral daily cy‑
clophosphamide requires more frequent blood 
monitoring (usually once or twice a week) with 
temporary suspension and appropriate dose re‑
duction in case of neutropenia (usually initially 
by 25 mg). It is recommended that all patients are 
given cotrimoxazole for the time of treatment, 
either 480 mg daily or 960 mg thrice weekly, to 
prevent Pneumocystis jiroveci (P. jiroveci) infection. 
In case of intolerance or contraindications to co‑
trimoxazole, alternatives include dapsone, ato‑
vaquone, or inhaled pentamidine, although they 
have not been shown to be cost ‑effective and are 
not generally recommended.
In 2 separate clinical trials published togeth‑
er, the efficacy of rituximab was demonstrated 
for renal and systemic disease.20,21 The trials are 
summarized in TABLE 2. It is perhaps the biggest 
change from the 2009 recommendations. How‑
ever, when compared to cyclophosphamide, re‑
mission is not induced any sooner and the inci‑
dence of serious adverse events is also unchanged. 
Although the clinical trial dose (and the li‑
censed dose) is as in TABLE 2, practically the use of 
the rheumatoid arthritis regimen is also permis‑
sible and we use that on a regular basis.
For patients with rapidly progressive renal in‑
volvement or pulmonary hemorrhage, plasma ex‑
change has been recommended in the past and 
remains an option. This remains a controversial 
topic because long ‑term follow ‑up of patients in 
the largest trial to date of plasma exchange in 
AAV fails to show significant benefit.22
Glucocorticoids are an essential part of remis‑
sion induction. The recommended initial dose of 
glucocorticoids is prednisolone 1 mg/kg/d (or 
equivalent) but not more than 60 mg/d, with 
gradual reduction to achieve daily prednisolone 
dose of 7.5 to 10 mg at 3 to 5 months. There is 
a strong possibility that the initial adverse effects 
of remission induction are related to glucocorti‑
coid treatment as evidenced by the similar rate of 
adverse events in the randomized controlled trial 
of rituximab vs cyclophosphamide.20
Remission maintenance therapy The treatment 
paradigm for AAV has mirrored that for can‑
cer. Thus, we use the phrases “remission induc‑
tion” and “remission maintenance”. This came 
Remission induction therapy Remission is defined 
as the absence of any disease activity.14 The as‑
sessment of disease state should be done by using 
a validated clinical tool such as Birmingham Vas‑
culitis Activity Score version 3 (BVASv3) or BVAS 
for Wegener’s granulomatosis (BVAS/WG).15,16 
AAV are usually associated with organ or life‑
‑threatening disease. The 2009 recommendations 
suggested that methotrexate use was reasonable 
for patients with localized disease. This was based 
on the results of a randomized controlled clinical 
trial that demonstrated noninferiority of metho‑
trexate to oral cyclophosphamide in this group.17 
However, this time the recommendations have 
differentiated even localized disease into that 
with and without cartilage and bony involvement, 
the argument being that destruction of nasal tis‑
sues is an organ ‑threatening manifestation. This 
argument is well founded in the long ‑term results 
of the above clinical trial. Not only did the cas‑
es in the methotrexate arm trend towards get‑
ting more relapses, but they also had a greater 
exposure to glucocorticoids and further immu‑
nosuppression.18 The authors have also given up 
using methotrexate unless the disease is genu‑
inely nonthreatening. The 2016 recommenda‑
tions provide example scenarios where it could 
be used: ENT disease without bony or cartilage 
involvement and without olfactory dysfunction 
or deafness, skin involvement without ulceration, 
skeletal muscle myositis, or noncavitating pulmo‑
nary disease without hemoptysis. Thus, as shown 
in FIGURE 1, patients with genuinely non ‑organ‑
‑threatening disease can be treated with metho‑
trexate or mycophenolate mofetil. Mycopheno‑
late mofetil could be used in the niche area of lo‑
calized disease where methotrexate might not be 
appropriate. The fall from grace of these 2 drugs is 
also noted in the grade of recommendation (B for 
methotrexate and C for mycophenolate mofetil). 
The majority of patients should therefore receive 
either cyclophosphamide or rituximab for remis‑
sion induction (FIGURE 1). 
Cyclophosphamide is the tried and tested rem‑
edy, which has been the drug that revolutionized 
the survival of patients with AAV.19 The authors 
use the pulsed intravenous regimen of 15 mg/kg 
intravenously (usually a maximum of 1200 mg), 
initial 3 pulses every 2 weeks, then every 3 
weeks. Daily oral cyclophosphamide at a dose 
of 2 mg/kg/d can also be used, but it delivers 
a much greater cumulative dose, with the resul‑
tant increase in the risk of toxicity. However, this 
TABLE 1 EUVAS trials pulsed cyclophosphamidea dose adjustment for age and renal 
function
Age, y Creatinine levels, <300 µmol/l Creatinine levels, 300–500 µmol/l
<60 15 mg/kg 12.5 mg/kg
60–70 12.5 mg/kg 10 mg/kg
>70 10 mg/kg 7.5 mg/kg
a Oral continuous cyclophosphamide dose should be reduced by 25% in patients 
older than 60 years and by 50% in those older than 70 years.
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induction was more effective than letting patients 
relapse. Patients who receive multiple doses of 
rituximab should have their immunoglobulin (Ig) 
levels monitored because the IgG levels will fall in 
the majority of cases.26 Currently, we advise that 
those patients be watched for the development 
of serious infections. In that scenario, it would 
be advisable to liaise with a clinical immunologist 
to use intravenous immunoglobulins.
As in remission induction, the previously rec‑
ommended dose of methotrexate, 20–25 mg/kg/
wk, and of mycophenolate mofetil, 2 g/d, finds 
less favor. While all 4 drugs have been recom‑
mended at Grade A, the consensus falls from 
94% for azathioprine, to 59% for rituximab, 
and to 53% for methotrexate and mycopheno‑
late mofetil.
into being because of the recognition that cyclo‑
phosphamide had unacceptable cumulative toxic‑
ity and therefore it was used for “inducing remis‑
sion”, but we needed a safer alternative for “main‑
taining remission”. The drug that has the best 
track record for this is azathioprine, which was 
shown to be safer than and as effective as cy‑
clophosphamide in a randomized controlled tri‑
al.23 This paradigm has now been challenged by 
the demonstration of the efficacy of rituximab 
in maintaining remission (TABLE 3). Guillevin et 
al24 successfully demonstrated that 5 pulses of 
low ‑dose rituximab over 18 months were supe‑
rior to azathioprine for maintaining remission 
in a randomized controlled trial. Smith et al25 
used a different dose of rituximab and showed 
that using rituximab for 2 years after remission 
TABLE 2 Overview of 2 randomized controlled trials of rituximab for remission induction in antineutrophil cytoplasmic antibody (ANCA) -associated 
vasculitides
Reference Patients Intervention Control Outcome
Jones et al20 new AAV, ANCA positive, 
renal involvement  
(n = 44)
RTX, 375 mg/m2/wk × 4
+
IV CYC, 15 mg/kg with 1st and 
3rd RTX
+
1 mg/kg/d pred reduced to 
5 mg at 6 months
(n = 33)
IV CYC, 15 mg/kg pulse at 0, 
2, 4, 7, 10, and 13 weeks, 
followed by AZA, 2 mg/kg/d
+
1 mg/kg/d pred reduced to 
5 mg at 6 months
(n = 11)
sustained remission in 25/33 
in intervention arm and 9/11 
in control arm at 12 months; 
no difference between the 2 
arms on superiority analysis 
(P = 0.68)
Stone et al21 new AAV, ANCA positive, 
BVAS/WG ≥3  
(n = 96)
RTX 375 mg/m2/wk × 4
+
daily placebo CYC followed by 
daily placebo AZA
+
1–3 pulses of 1 g IV MP 
followed by 1 mg/kg/d pred 
reduced to 0 mg at 6 months
(n = 48)
placebo RTX
+
daily oral CYC 2 mg/kg/d 
followed by AZA 2 mg/kg/d 
after 3–6 months
+
1 mg/kg/d pred reduced to 
5 mg at 0 months
(n = 48)
sustained remission in 29/48 
in intervention arm and 
31/48 in control arm at 6 
months
Abbreviations: AAV, ANCA ‑associated vasculitis; ANCA, antineutrophil cytoplasmic antibody; AZA, azathioprine; BVAS/WG, Birmingham Vasculitis 
Activity Score for Wegener’s granulomatosis; CYC, cyclophosphamide; MP, methylprednisolone; pred, prednisolone; RTX, rituximab
TABLE 3 Overview of clinical trials of rituximab for remission maintenance in antineutrophil cytoplasmic antibody -associated vasculities
Reference Patients Intervention Control Outcome
Guillevin et al24 new or relapsing GPA/MPA
complete remission
post -pulsed CYC
ANCA -positive or histology
(n = 115)
RTX at day 0, 14; months 
6, 12, 18
(n = 57)
AZA 2 mg/kg/d for 12 
months then
1.5 mg/kg/d for 6 months 
then
1 mg/kg/d for 4 months
(n = 58)
at month 28, 3/57 relapsed 
in intervention arm, 7/58 
relapsed in control arm
hazard, 6.61 (1.56–27.96)
Smith et al25 GPA/MPA
ANCA -positive or histology
one of the following:
• never achieved remission
• relapsing disease on standard 
immunosuppression
• standard therapies contraindicated
• partial remission needing >10 mg/d 
pred
(n = 73)
RTX 375 mg/m2/wk × 4
OR
RTX 1g/2 weeks × 2
followed by repeat RTX 1 g 
every 6 months for 2 
years
(n = 28)
RTX 375 mg/m2/wk × 4
OR
RTX 1g/2 weeks × 2
followed by repeat RTX 
at clinical relapse
(n = 45)
at 48 months, 11/43 
relapse in intervention 
arm, 21/26 relapse in 
control arm
P <0.001
Abbreviations: GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; others, see TABLE 2
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and vice versa, is recommended.29 In patients who 
do not respond to pulsed cyclophosphamide and 
fail on rituximab, or rituximab is not available, 
continuous oral cyclophosphamide therapy may 
be considered.30 Patients who fail to achieve full 
remission and remain in the state of persistent 
low disease activity may benefit from adjunc‑
tive therapy with intravenous immunoglobulins 
(0.4 g/kg for 5 days; total of 2 g per cycle). How‑
ever, it is important to recognize potential pit‑
falls related to presumed refractoriness. The first 
and most obvious question is whether the diagno‑
sis of AAV is correct and treatment regimen ad‑
equate, and secondly, whether symptoms are re‑
lated to active disease as opposed to damage, in‑
fection, or other comorbidity (eg, malignancy). 
Good examples of symptoms that may represent 
damage rather than active disease are persistent 
ENT symptoms, proteinuria, or chronic neurop‑
athy. Similarly, exacerbation of ENT symptoms 
or new lung infiltrates may reflect infective com‑
plication and not a flare of vasculitis. As a rule of 
a thumb, refractory patients should be treated in 
close collaboration with an expert center or re‑
ferred to such center for evaluation and consid‑
eration of experimental therapies.
Long ‑term monitoring Improving survival means 
that the prevalence of AAV is rising. Long ‑term 
problems of a chronic inflammatory disease are 
becoming apparent. At every follow ‑up visit, a pa‑
tient suffering from AAV should have their urine 
checked. Those patients thought to have nonglo‑
merular hematuria should be referred for a uro‑
logical examination, especially if there is a histo‑
ry of cyclophosphamide exposure. In those with 
prior rituximab, immunoglobulin levels may need 
monitoring and treating if they suffer with severe 
infections. The risk of post ‑rituximab P. jirovecii 
pneumonia is low.31 However, there is some ev‑
idence from the hematology literature that re‑
peated rituximab ‑based chemotherapy puts pa‑
tients at a higher risk of P. jirovecii pneumonia, 
and the risk can be mitigated with addition of co‑
trimoxazole.32 The authors commence P. jirovecii 
prophylaxis in those patients who have an IgG 
level of less than 6 g/l.
Cardiovascular risk factors should be assessed 
regularly as should other problems related to long‑
‑term glucocorticoid and immunosuppressive use 
(type 2 diabetes, osteoporosis, cancer).7,33
Relapsing disease Relapse is an unfortunate part 
of AAV. The relapse rate rises from about 20% 
at 12 months to about 60% at 5 years.27 The best 
evidence for the treatment of relapsing disease is 
part of the subanalysis of the American rituximab 
trial (TABLE 4).21 The majority of these patients had 
already received cyclophosphamide for their new 
disease. Therefore, the authors suggest that ritux‑
imab is used in preference to cyclophosphamide 
in those patients who relapse after prior cyclo‑
phosphamide use. It is also worth noting that 
the consensus for the voting in the 2016 recom‑
mendations is higher for rituximab (94%, Grade 
A) than for cyclophosphamide (88%, Grade A).
In the past, there has been a trend to treat mi‑
nor relapses with a short course of increment in 
the glucocorticoid dose. However, there is rec‑
ognition that this is perhaps a bad strategy just 
as it is so for patients with rheumatoid arthri‑
tis. Miloslavsky et al28 demonstrated that these 
patients with “minor relapses” treated with an 
increase in their glucocorticoid dose had a high 
rate of severe relapse. Therefore, the 2016 rec‑
ommendations suggest that even minor relaps‑
es should be treated with a change in immuno‑
suppressive regimen.
The current general consensus is to discontinue 
rituximab remission maintenance after 2 years. 
Similarly, the EULAR/ERA ‑EDTA task force also 
concluded that other immunosuppressive agents 
should be continued for at least 2 years, after 
which gradual taper could be considered. This rec‑
ommendation was made purely on the basis of ex‑
pert opinion rather than evidence. But the con‑
sensus was strongest for PR3 ‑persistent disease. 
For other ANCA states during remission, the ex‑
perts tended to start tapering immunosuppres‑
sion even before the 2 years were up.
Refractory disease In most cases, remission 
can be achieved within 3 months, although in 
some cases it may take longer. No improvement 
in 4 weeks or improvement of less than 50% in 
6 weeks of treatment (as measured by a validat‑
ed clinical tool such as BVASv3 or BVAS/WG), or 
chronic persistent disease (defined as the presence 
of at least 1 major or 3 minor items on the disease 
activity score) after more than 12 weeks of treat‑
ment is consistent with refractory disease14 and 
warrants change in therapy. In patients treated 
with cyclophosphamide, a switch to rituximab, 
TABLE 4 Subanalysis of the efficacy of rituximab in relapsing ANCA -associated vasculitis in the RAVE trial
Reference Patients Intervention Control Outcome
Stone et al21 relapsing AAV
ANCA positive
BVAS/WG ≥3
(n = 101)
RTX 375 mg/m2/wk × 4
+
daily placebo CYC followed by 
daily placebo AZA
+
1–3 pulses of 1 g IV MP followed 
by 1 mg/kg/d pred reduced to 
0 mg at 6 months
(n = 51)
placebo RTX
+
daily oral CYC 2 mg/kg/d 
followed by AZA 2 mg/kg/d 
after 3–6 months
+
1 mg/kg/d pred reduced to 5 mg 
at 0 months
(n = 50)
sustained remission in 34/51 in 
intervention arm and 21/50 in 
control arm at 6 months
superiority of intervention proven
odds ratio, 1.4 (1.03–1.91) 
P = 0.03
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1 These conditions are rare and their manage‑
ment is challenging. The management should be 
either at or in conjunction with an expert center.
2 Glucocorticoid therapy is an extremely impor‑
tant adjunct for the management of AAV, but it 
is also responsible for the majority of adverse ef‑
fects. It should be tapered down to 7.5 to 10 mg/d 
at 3 to 5 months. The temptation to treat a “mi‑
nor relapse” with glucocorticoid alone should be 
resisted.
3 Rituximab can be used for remission induc‑
tion and maintenance, changing our paradigm of 
the way that AAV has been treated so far. It can 
lead to a hypoimmunoglobulinemic state, and 
IgG levels should be monitored.
4 Most patients will not be suitable for treat‑
ment with therapies besides cyclophosphamide 
or rituximab.
5 Monitoring of these patients should be holis‑
tic with a structured assessment tool and moni‑
toring for effects related to the vasculitis as well 
as treatment. Serial ANCA monitoring should not 
guide treatment changes.
6 Involve patients in decision making at every 
stage and ensure that they have access to the ed‑
ucational resources they need to make the best 
of a long ‑term potentially life ‑threatening chron‑
ic condition.
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At every follow ‑up, disease assessment should 
be led by a structured interview with the help of 
a validated assessment tool such as BVASv3 or 
BVAS/WG rather than ANCA monitoring. Clini‑
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STRESZCZENIE
European League Against Rheumatism (EULAR) z European Renal Association-European Dialysis and 
Transplant Association (ERA‑EDTA) opublikowały niedawno uaktualnienie zaleceń EULAR z 2009 r. 
dotyczące postępowania w zapaleniach naczyń związanych z obecnością przeciwciał przeciw cytoplazmie 
neutrofilów (antineutrophil cytoplasmic antibody (ANCA)-associated vasculitides – AAV). W poniższym 
artykule omówiono główne przesłania kliniczne wynikające z tych zaleceń: 1) w celu potwierdzenia 
nowego rozpoznania lub nawrotu AAV, jeśli to możliwe należy wykonać biopsję narządu; 2) glikokor-
tykosteroidy (GKS) są bardzo ważnym elementem leczenia AAV, ale są odpowiedzialne za większość działań 
niepożądanych; docelowa dawka GKS po 3–5 miesiący leczenia wynosi 7,5–10 mg/d; 3) cyklofosfamid 
lub rytuksymab stanowią podstawę leczenia indukującego remisję; 4) chorych z ciężkim zaostrzeniem 
powinno się leczyć tak samo jak tych z nowym rozpoznaniem, ale u pacjentów z nawrotem choroby 
po leczeniu cyklofosfamidem preferuje się rytuksymab; 5) w przypadku łagodnego zaostrzenia należy 
rozważyć zmianę leku immunosupresyjnego, a nie jedynie zwiększenie dawki GKS; 6) rytuksymab można 
stosować nie tylko w celu indukcji remisji, ale także jej podtrzymania; 7) leczenie podtrzymujące remisję 
należy prowadzić przez co najmniej 2 lata i po tym czasie rozważyć stopniowe zmniejszanie dawek 
leków aż do ich odstawienia; 8) ANCA są bardzo pomocne w ustaleniu rozpoznania, a zwiększenie ich 
stężenia łączy się z ryzykiem nawrotu choroby, niemniej nie wolno używać seryjnych pomiarów stężeń 
ANCA do podejmowania decyzji leczniczych; 9) monitorowanie chorych na AAV powinno obejmować 
różne aspekty choroby, w tym jej skutki i działania niepożądane leków; do tego celu zaleca się używanie 
złożonych narzędzi oceny klinicznej; 10) diagnostykę i leczenie chorych na AAV powinno się prowadzić 
w porozumieniu z ośrodkiem eksperckim lub w takim ośrodku; 11) pacjenci z AAV powinni brać udział 
w podejmowaniu decyzji dotyczących ich leczenia i mieć dostęp do źródeł edukacyjnych.
